Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 9, Issue 12, Pages 1230-1234Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.8b00382
Keywords
Cancer; KRAS; G12C; covalent
Categories
Ask authors/readers for more resources
KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly associated with poor prognosis and resistance to standard treatment. The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research. Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small molecules that covalently modify the mutated codon 12 cysteine is feasible. We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity. The PK/PD and efficacy of compound 13 will be highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available